Uncategorized

Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal

Published

on

For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is ending that holdout with the proposed $1.5 billion deal for Myricx.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version